LabGenius is a privately held, synthetic biology company based in London, UK. It uses a combination of artificial intelligence, DNA synthesis, and robotics to discover high-value biological molecules.
The company's novel technology is able to produce trillions of variations of gene sequences, which can be used to create new biological materials using artificial intelligence. It can predict which gene mutations will improve a biological design, thereby enabling scientists to produce new therapeutics or other materials such as adhesives, catalysts, and sensors.
LabGenius, in partnership with leading multinationals, is developing various products, focusing on the areas of biotherapeutics, advanced materials, and personal care. In the biotherapeutics category, LabGenius' AI-driven evolution engine, EVA, is learning how to optimally enhance the stability of therapeutic proteins in protease rich environments such as the GI tract, tumor microenvironments, and inflammed tissues. The end goal is to enable the delivery of novel therapies for unmet clinical needs.
In the advanced materials area, engineered proteins can be used to form high value coatings, adhesives, fibres, catalysts, and sensors. LabGenius has completed several development projects in this area and are engaged in collaborative development with aerospace and defence companies.
Timeline
Funding rounds
People
Dr. Adam Tomassi-Russel
Chief Commercial Officer
Dr. Annelie Oswald
Platform Scientist
Dr. Ben Mackrow
Synthetic Biologist
Dr. Chris Cozens
Molecular Biologist
Dr. Eyal Kazin
Data Scientist
Dr. Fiona Rowan
Biologics Scientist
Dr. Katya Putintseva
Data Scientist
Dr. Maria Bagniewska
Program Manager
Dr. Pedro Tizei
Automation Scientist
Dr. Pierre-Yves Colin
Molecular Biologist
Dr. Richard Menzies-Wilson
Operations Manager
Eddie Li
Full Stack Developer
George Morriss
Employee
Harry Rickerby
CSO
James Field
Founder & CEO
Leila Zegna
Investor Director
Mo Niknafs
Head of Non-Dilutive Financing
Oli Hall
Employee
Philipp Moehring
Investor
Staffan Piledahl
Software Engineer
Further reading
LabGenius Locks Down $3.66m From Top-Tier Investors To Harness Evolution - SynBioBeta
Web
Documentaries, videos and podcasts
Companies
LabGenius
James Field
London, England, United Kingdom
Machine learning for protein therapeutics